Henrik Daub

Company: NEOsphere Biotechnologies GmbH

Job title: Chief Scientific Officer

Seminars:

Systematic Discovery of Novel Degraders Through Deep Proteomic Screening 4:15 pm

High-throughput proteomics rapidly establishes broad pipelines of novel, high-value degrader targets at scale and within native cells, employing a target- and E3 ligase-unbiased approach It facilitates the identification of novel degrader targets, monitoring of proteome-wide selectivity, and detection of molecules acting through new E3 ligases and emerging TPD mechanisms Global ubiquitinomics reveals degrader-induced modifications at…Read more

day: Day 1, PM